<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650923</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00678</org_study_id>
    <secondary_id>NCI-2009-00678</secondary_id>
    <secondary_id>CDR0000590174</secondary_id>
    <secondary_id>NABTC-07-01</secondary_id>
    <secondary_id>NABTC07-01</secondary_id>
    <secondary_id>NABTC-07-01</secondary_id>
    <secondary_id>U01CA137443</secondary_id>
    <nct_id>NCT00650923</nct_id>
  </id_info>
  <brief_title>Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma</brief_title>
  <official_title>Phase I Trial of Aflibercept (VEGF Trap) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of aflibercept when given&#xD;
      together with radiation therapy and temozolomide in treating patients with newly diagnosed or&#xD;
      recurrent glioblastoma multiforme, gliosarcoma, or other malignant glioma. Aflibercept may&#xD;
      stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses&#xD;
      high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving aflibercept together with radiation therapy and&#xD;
      temozolomide may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To define the maximum tolerated dose (MTD) of aflibercept (VEGF Trap) with radiotherapy&#xD;
      (RT) and concurrent temozolomide (TMZ) when administered in patients with newly-diagnosed&#xD;
      glioblastoma (GBM) or gliosarcoma.&#xD;
&#xD;
      II. To define the MTD of aflibercept with adjuvant TMZ administered at 150mg/m2once daily for&#xD;
      5 days every 28 days in patients with stable or recurrent malignant glioma (MG) after RT.&#xD;
&#xD;
      III. To define the MTD of aflibercept with adjuvant TMZ administered at 100 mg/m2 once daily&#xD;
      for 21 days every 28 days in patients with stable or recurrent MG after RT.&#xD;
&#xD;
      IV. To characterize the safety profile of aflibercept in combination with RT and concomitant&#xD;
      TMZ in patients with newly-diagnosed GBM.&#xD;
&#xD;
      V. To characterize the safety profile of aflibercept in combination with adjuvant TMZ in&#xD;
      patients with stable or recurrent MG after RT.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To characterize the pharmacokinetic profiles of free and bound aflibercept and TMZ in&#xD;
      these patients&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of aflibercept. Patients are assigned&#xD;
      to 1 of 3 treatment groups according to prior treatment and diagnosis.&#xD;
&#xD;
      Group 1 (newly diagnosed glioblastoma multiforme or gliosarcoma): Patients undergo involved&#xD;
      field partial brain radiotherapy (RT) once daily, 5 days a week (total of 30 fractions) and&#xD;
      receive concurrent oral temozolomide (TMZ) once daily for 6 weeks. Beginning 2 weeks after&#xD;
      the initiation of RT patients also receive aflibercept IV over 1 hour on days 1 and 15 and&#xD;
      continue until the end of RT. Beginning 4 weeks after completion of radiotherapy, patients&#xD;
      receive adjuvant oral TMZ once daily on days 1-5. Treatment with adjuvant TMZ repeats every&#xD;
      28 days for up to 12 courses.&#xD;
&#xD;
      Group 2 (stable or recurrent malignant glioma): Patients undergo radiotherapy as in group 1.&#xD;
      Patients receive oral TMZ on days 1-5. Treatment repeats every 28 days for up to 12* courses.&#xD;
      Patients also receive aflibercept IV over 1 hour on days 1 and 15 beginning on the first day&#xD;
      of TMZ treatment.&#xD;
&#xD;
      [Note: *The 12 course maximum includes adjuvant TMZ courses administered prior to&#xD;
      enrollment.]&#xD;
&#xD;
      Group 3 (stable or recurrent malignant glioma): Patients undergo radiotherapy as in group 1.&#xD;
      Patients receive oral TMZ on days 1-5. Treatment repeats every 21 days for up to 12* courses.&#xD;
      Patients also receive aflibercept IV over 1 hour on days 1 and 15 beginning on the first day&#xD;
      of TMZ treatment.&#xD;
&#xD;
      [Note: *The 12 course maximum includes adjuvant TMZ courses administered prior to&#xD;
      enrollment.]&#xD;
&#xD;
      In all groups, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Blood samples are collected periodically for analysis of pharmacokinetics by ELISA. Tumor&#xD;
      biomarkers and plasma angiogenic peptides are analyzed for correlation with response, and&#xD;
      tumor MGMT promoter methylation status is determined using methylation-specific PCR.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of aflibercept defined as the dose at which fewer than one-third of patients experience DLT based on the CTC severity grading</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy in terms of antitumor activity based on clinical, radiographic, and biologic assessments</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Descriptive analysis will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma aflibercept (VEGF Trap) concentrations and PK parameters such as Cmax, Tmax, area under the plasma concentration-time curve (AUCo-t and AUC), clearance (CL), apparent volume of distribution at steady state (Vdss), and terminal half-life (t1/2)</measure>
    <time_frame>Baseline and days 15, 16, 22, 29, 57, 85 of course 1 for patients in Arm I; baseline and days 2, 8, 15, 43, 71 of course 1 for patients in Arms 2 and 3</time_frame>
    <description>Will be determined using non-compartmental methods. Dose proportionality in PK parameters will be determined by performing a one-way analysis of variance (ANOVA) on dose-normalized parameters. In addition, summary tables depicting individual patient concentrations and individual and mean PK parameters will be provided.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziv-aflibercept</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>aflibercept</other_name>
    <other_name>vascular endothelial growth factor trap</other_name>
    <other_name>VEGF Trap</other_name>
    <other_name>Zaltrap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo RT</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>SCH 52365</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
          -  Creatinine &lt; = 1.5 mg/dL or creatinine clearance = &gt; 60 mL/min&#xD;
&#xD;
          -  At least 28 days since prior major surgery or open biopsy&#xD;
&#xD;
          -  INR &lt; = 1.5&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  SGOT and SGPT &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 2 times ULN&#xD;
&#xD;
          -  Life expectancy = &gt; 12 weeks&#xD;
&#xD;
          -  WBC = &gt; 3,000/μL&#xD;
&#xD;
          -  ANC= &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count = &gt; 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin = &gt; 10 g/dL (transfusion allowed)&#xD;
&#xD;
          -  At least 21 days since prior radiotherapy (groups 2 and 3)&#xD;
&#xD;
          -  No prior Gliadel® wafers&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to, during, and for at least 6&#xD;
             months after completion of study treatment&#xD;
&#xD;
          -  At least 28 days since prior significant traumatic injury No evidence of bleeding&#xD;
             diathesis or coagulopathy&#xD;
&#xD;
          -  No serious or nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No history of other cancer (except nonmelanoma skin cancer or carcinoma in situ of the&#xD;
             cervix), unless in complete remission and off of all therapy for that disease for a&#xD;
             minimum of 3 years&#xD;
&#xD;
          -  No history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess&#xD;
             gastrointestinal bleeding or diverticulitis within the past 6 months&#xD;
&#xD;
          -  No prior cranial radiotherapy (group 1 only)&#xD;
&#xD;
          -  No prior aflibercept&#xD;
&#xD;
          -  No prior treatment for brain tumors, except concurrent radiotherapy and temozolomide&#xD;
             or 2 or fewer 28-day courses of adjuvant temozolomide (groups 2 and 3)&#xD;
&#xD;
          -  No prior or concurrent cytotoxic drug therapy, non-cytotoxic drug therapy, or&#xD;
             experimental drug therapy for brain tumors (group 1 only)&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
          -  No known hypersensitivity to CHO cell products or other recombinant human antibodies&#xD;
&#xD;
          -  No history of hypersensitivity to a recombinant protein whereby reaction occurs during&#xD;
             or immediately after infusion&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to other study agents&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection or psychiatric illness or social situation that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  No clinically significant cardiovascular disease within the past 6 months, including&#xD;
             any of the following:&#xD;
&#xD;
        History of ischemic or hemorrhagic stroke&#xD;
&#xD;
          -  Myocardial infarction, coronary artery bypass graft, or unstable angina&#xD;
&#xD;
          -  New York Heart Association class III-IV congestive heart failure, serious cardiac&#xD;
             arrhythmia requiring medication, or unstable angina pectoris&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Pulmonary embolism, deep vein thrombosis, or other thromboembolic event&#xD;
&#xD;
          -  No disease that will obscure toxicity or dangerously alter drug metabolism&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 28 days since prior and no concurrent investigational agents&#xD;
&#xD;
          -  More than 7 days since prior core biopsy&#xD;
&#xD;
          -  At least 23 days since prior temozolomide (groups 2 and 3)&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent full-dose anticoagulants (e.g., warfarin or low molecular-weight&#xD;
             heparin)&#xD;
&#xD;
          -  Prophylactic doses allowed&#xD;
&#xD;
          -  No concurrent routine prophylactic use of filgrastim (G-CSF)&#xD;
&#xD;
          -  No other concurrent anticancer therapy (including chemotherapy, radiotherapy, hormonal&#xD;
             treatment, or immunotherapy)&#xD;
&#xD;
          -  Concurrent enzyme-inducing antiepileptic drugs (EIAED) or non-EIAED allowed&#xD;
&#xD;
          -  Urine protein:creatinine ratio &lt; = 1 or 24-hour urine protein &lt; = 500 mg&#xD;
&#xD;
          -  No significant medical illnesses that in the investigator's opinion cannot be&#xD;
             adequately controlled with appropriate therapy or would compromise the patient's&#xD;
             ability to tolerate therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Wen</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles (UCLA )</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult Brain Tumor Consortium</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Aflibercept</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

